查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198722

静脉曲张治疗市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)

Varicose Veins Treatment Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的预测期内，静脉曲张治疗市场预计将以 6.0% 的复合年增长率增长。

COVID-19 的爆发预计将对市场产生重大影响，因为医护人员的工作重心已转移到治疗 COVID-19 感染者上。 因此，非紧急情况的治疗已成为次要事项。 根据一项名为“COVID-19 时代静脉实践的变化”的研究。 根据 2021 年 5 月发表在 Annals of Vascular Surgery 上的“Never Let a Good Crisis Go to Waste”，在 COVID-19 封锁期间，国民健康保险和私立医院因静脉曲张及其并发症而停止治疗。 麻醉师会议的短缺导致静脉曲张手术的数量显着减少，麻醉师全神贯注于紧急情况，包括 COVID 和非 COVID。 一般来说，老年人口和有合併症的人更容易患上静脉疾病，如静脉曲张。 这些人感染 SARS-CoV-2 病毒的风险也增加。 因此，大多数与静脉曲张治疗相关的干预措施在大流行期间被保留和推迟，预计这将对研究市场增长产生重大影响。

静脉曲张治疗市场主要是由于普通人群越来越喜欢这种微创手术、老年人口不断增加以及用于这种治疗的设备技术进步。受以下因素驱动：

此外，静脉疣患病率上升预计将推动市场增长。 2020 年 2 月发表在 BMC Nursing 上的一篇研究论文“Dhulikhel 医院护士的静脉曲张及其危险因素：一项横断面研究”表明，静脉曲张被认为是最常见的慢性静脉疾病之一。估计全世界有 20-60% 的成年人受到影响。 此外，根据 2020 年 5 月在沙特阿拉伯艾卜哈的《家庭医学和初级保健杂誌》上发表的题为“沙特阿拉伯艾卜哈教师静脉曲张的患病率和意识”的研究，近 42% 的教师参加了该研究被诊断为静脉曲张。 肥胖、长时间站立工作和吸烟，尤其是女性，已被确定为与静脉曲张发展相关的一些重要风险因素。 此外，由于怀孕期间妊娠子宫增大，已观察到高血压和下肢静脉肿胀以及激素分泌增加削弱静脉壁，导致静脉曲张的诊断。

静脉曲张在老年人群中最常见，随着老年人口的增加，预计将进一步推动市场。 根据世界卫生组织 2021 年的数据，2015 年至 2050 年间，世界 60 岁及以上人口的比例将从 12% 增加近一倍至 22%。 到 2050 年，全球 80% 的老年人将生活在低收入和中等收入国家。 衰老的速度比过去快了很多。

此外，预计主要市场参与者会增加产品公告，从而推动市场增长。 例如，2020年10月，专注于迴声疗法（使用高强度聚焦超声或HIFU）的创新公司THERACLION推出了第二代SONOVEIN，这是针对静脉曲张的HIFU治疗方案，获得了CE标誌。

由于技术的进步和医疗保健系统的改进，预计该市场在预测期内将稳步增长。 然而，与静脉手术相关的高成本和风险预计会阻碍市场。

静脉曲张治疗市场趋势

预计激光烧蚀设备在预测期内将大幅增长

激光消融治疗为接受静脉曲张治疗的患者提供了显着的好处，因为它不涉及长期住院或恢復过程中的不适。 借助新技术和研究市场主要参与者研究活动的进步，越来越多地采用激光治疗静脉曲张。

激光消融技术使医生能够闭合细小的静脉曲张和蜘蛛状静脉。 这种治疗涉及向静脉发射强烈的光，使受影响的静脉消失或褪色。 由于医疗成本上升和非侵入性手术的增长趋势，发达国家对激光疗法的使用正在增加。 2022 年 5 月发表在英国外科杂誌上的一项题为“浅静脉功能不全治疗后的压缩：系统评价”的研究发现，激光消融具有成本效益，并且与隐静脉反流有关。它被认为是首选的初始治疗治疗直径 >3 毫米的有症状静脉曲张。 此外，本地静脉曲张激光器製造商之间的竞争非常激烈。 随着激光的未来发展和激光治疗的简便性，预计该细分市场将在未来增长。

此外，预计主要市场参与者增加产品发布将在预测期内推动该细分市场的增长。 例如，2022 年 4 月，专注于开髮用于治疗血管疾病的准分子激光系统的医疗设备公司 Ra Medical Systems, Inc. 宣布，美国专利商标局已授予该公司一种液体填充激光器，该激光器具有扩展的远端光学窗口。据报导，它已获得激光烧蚀专利。

因此，由于上述因素，预计激光烧蚀设备市场在预测期内将实现健康增长。

预计在预测期内北美将主导市场

北美所占份额最大，预计这一趋势在预测期内将持续下去。 促进北美静脉曲张治疗市场增长的主要因素包括美国等国家/地区发达的医疗保健系统以及能够增加市场产品可用性的主要参与者的存在。提到。 此外，由于有利的报销方案，美国人可以以负担得起的费用获得这种治疗。

根据 2021 年 12 月在《临床流行病学和全球健康》杂誌上发表的一项题为“城市警察静脉曲张风险评估——一项横断面研究”的研究，静脉曲张影响了美国大约 23% 的成年人。影响。 考虑到蜘蛛状毛细血管扩张和网状静脉，其患病率在男性中上升至 80%，在女性中上升至 85%。 原来美国是22分之一。 因此，预计在预测期内，美国人口中静脉曲张负担的增加将推动北美地区的研究市场。

然而，儘管主要市场参与者为市场扩张而采取的各种策略（例如产品发布、併购和合作）有望提振区域市场。 例如，2021 年 4 月，Medtronic 启动了一项调查设备豁免 (IDE) 试验，以了解用于治疗深静脉疾病的 Abre Vein 自扩张支架系统是否有效和安全。 此外，2021 年 12 月，一家专注于静脉反流病创新治疗程序的私人控股硅谷医疗器械公司 Venclose Inc. 宣布推出一种针对不完全穿通静脉 (IPV) 的新型微创治疗方法。我们已获得 FDA 批准射频消融 (RFA) 导管 Venclose Maven 的 510(k) 许可。

因此，由于上述因素，静脉曲张治疗市场有望在预测期内实现健康增长。

静脉曲张治疗市场竞争者分析

静脉曲张治疗市场竞争适中，主要由本地公司组成。 儘管有少数国际公司，但来自不同地区的本地公司主导了整个市场。 随着医疗器械市场的不断增长，预计在预测期内将有更多公司研究和渗透市场并占据相当大的份额。 市场上的主要参与者包括 Medtronic plc、AngioDynamics Inc.、Teleflex incorporated、Lumenis、Quanta System、Biolitec AG、Syneron Medical Ltd 和 Vascular Solutions Inc。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 越来越喜欢微创手术
    • 设备的技术进步
    • 不断增长的老年人口
  • 市场製约因素
    • 手术费用高
    • 与静脉手术相关的风险
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按治疗类型
    • 静脉消融
    • 注射硬化疗法
    • 手术结扎/解剖
  • 按产品分类
    • 消融设备
      • 射频消融设备
      • 激光烧灼装置
    • 静脉闭合
    • 外科产品
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Candela Medical（Syneron Medical Ltd）
    • Medtronic PLC
    • Boston Scientific（Lumenis Corporation）
    • El. En SpA Group（Quanta System）
    • Teleflex Incorporated
    • Eufoton SRL
    • Biolitec AG（BioMed Technology Holdings Ltd）
    • AngioDynamics Inc.
    • Alma Lasers Ltd
    • Sciton Inc.
    • Won Tech Co. Ltd
    • Dornier MedTech GmbH

第七章市场机会与未来趋势

简介目录
Product Code: 67124

The varicose veins treatment market is expected to register a CAGR of 6.0% over the forecast period, 2022-2027.

The outbreak of COVID-19 is expected to impact the market significantly, as the focus of healthcare professionals has been shifted toward the treatment of COVID-19-infected patients. Thus, the treatment of non-emergency medical conditions was given lesser priority. According to the study titled "Changing Venous Practice in the COVID-19 Era: "Never Let a Good Crisis Go to Waste" published in the Annals of Vascular Surgery in May 2021, The national health services hospital and private hospitals stopped treating people with varicose veins and their complications during the COVID-19 Lockdown. Due to a lack of anesthetic sessions, the number of varicose vein surgeries has decreased significantly, with anesthetists being preoccupied with emergency cases, both COVID and non-COVID. Also, the geriatric population and people with co-morbid conditions are generally prone to develop venous diseases, such as varicose veins. This population is also at higher risk of being infected by the SARS-CoV-2 virus. Hence, most of the interventions related to the treatment of varicose veins are reserved and deferred during the pandemic, which is expected to significantly impact the growth of the studied market.

The market for the treatment of varicose veins is majorly driven by factors such as the growing preference of the general population for minimally-invasive surgeries, the rising geriatric population, and the technological advancements in the devices used for this treatment.

Furthermore, rising prevalence of the vericose vein anticipated to drive the growth of the market. According to a research article titled "Varicose veins and its risk factors among nurses at Dhulikhel hospital: a cross sectional study" published in BMC Nursing in February 2020, varicose veins are considered one of the most common chronic venous disorders, affecting 20-60% of all adults globally. Additionally, according to the study titled "Prevalence and awareness of varicose veins among teachers in Abha, Saudi Arabia" published in the Journal of Family Medicine and Primary Care May 2020 nearly 42% of the teachers who participated in a research study were diagnosed with varicose veins in Abha, Saudi Arabia. Obesity, particularly among women, prolonged standing hours at work, and smoking, are some of the significant risk factors associated with the development of varicose veins. Additionally, varicose veins are observed to be diagnosed during pregnancies due to the enlargement of the gravid uterus, which results in hypertension and distension in the lower-extremity veins and an increase in hormone secretion, leading to the weakening of the venous walls.

Vericose vein is most prevalent in the geriatric population, moreover rising in geriatric population anticipated to boost the market. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. By 2050, 80% of the world's elderly will live in low- and middle-income countries. The population is aging at a much faster rate than in the past.

Additionaly, growing product launches by the key market players anticipated to boost the market growth. For Instance in October 2020, THERACLION an innovative company specialized in echotherapy treatment (using High Intensity Focused Ultrasound or HIFU), has obtained CE Mark for the second generation of SONOVEIN, it's HIFU treatment solution for varicose veins.

With technological advancements and the growing focus on improvising the healthcare system, the market is expected to witness steady growth over the forecast period. However, the high costs and risks associated with the procedures involved in vein surgeries are expected to hinder the market.

Varicose Veins Treatment Market Trends

Laser Ablation Devices Expected to Witness Considerable Growth Over the Forecast Period

Laser ablation treatment does not involve lengthy hospital stays or discomfort during the recovery process, which provides significant benefits to the patients who are treated for varicose veins. With the help of novel technologies and advancements in research activities by the key players in the studied market, there has been increased adoption of lasers in the treatment of varicose veins.

Laser ablation technology enables doctors to close smaller varicose veins and spider veins. This treatment involves emitting strong bursts of light onto the vein, making the affected veins disappear or fade. The use of laser treatment is increasing in developed nations due to the increasing healthcare expenditure and the growing inclination toward non-invasive procedures. According to a research study titled " Compression following treatment of superficial venous incompetence: systematic review" published in the British Journal of Surgery in May 2022, laser ablation therapy was cost-effective and the preferred initial treatment for symptomatic varicose veins having a diameter of at least 3 mm, with evidence of saphenous vein reflux. Also, there is intense competition among the local manufacturers of varicose vein lasers. With the upcoming advancements in lasers and the ease of treatment provided by the same, it is expected that the segment will grow in the future.

Moreover, increasing product launch by the key market players anticipated to boost the segment growth over the forecast period. For Instance, in April 2022, Ra Medical Systems, Inc., a medical device company focusing on developing its excimer laser system to treat vascular diseases, reported the United States Patent and Trademark Office has granted the company a patent for liquid-filled laser ablation with expanded distal optical windows.

Thus, owing to the aforementioned factors, the laser ablation devices market is expected to register healthy growth over the forecast period.

North America Expected to Dominate the Market Over the Forecast Period

North America holds the largest share of the market studied, and this trend is expected to continue over the forecast period. The major factors contributing to the growth of the varicose veins treatment market in North America include the well-developed healthcare systems in countries such as the United States and the presence of major players, which allows the higher availability of products in the market. Furthermore, due to the favorable reimbursement scenario, the people in the United States can access this treatment at an affordable cost.

According to the study titled "Risk assessment for varicose veins among city Police-A cross-sectional study" published in the Clinical Epidemiology and Global Health in December 2021, Varicose veins affect roughly 23% of adults in the United States. When spider telangiectasias and reticular veins are taken into account, the prevalence rises to 80% in men and 85% in women. The United States of America was found to be 1 in 22. Thus, the increasing burden of varicose veins in the American population is expected to drive the studied market in the North American region over the forecast period.

However, various strategies adopted by the key market players for market expansion such as product launch, merger and acquisition, collaboration and among other anticipated to boost the market in the region. For instance in April 2021, Medtronic has started an Investigation Device Exemption (IDE) study to see if the Abre venous self-expanding stent system, which is used to treat deep venous diseases, is effective and safe. Additionally, in Otober 2021, Venclose Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease recieved FDA 510(k) clearance for Venclose Maven, a novel radiofrequency ablation (RFA) catheter for minimally invasive treatment of incompetent perforator veins (IPVs).

Thus, owing to the aforementioned factors, the vericose vein treatment market is expected to register healthy growth over the forecast period.

Varicose Veins Treatment Market Competitor Analysis

The market for varicose vein treatment is moderately competitive and comprises mostly local players. A few international companies are present, but the local companies in different geographies majorly control the overall market. With the growing medical devices market, it is predicted that more companies will penetrate the market studied and hold substantial shares over the forecast period. The major players of the market include Medtronic plc, AngioDynamics Inc., Teleflex incorporated, Lumenis, Quanta System, Biolitec AG, Syneron Medical Ltd, and Vascular Solutions Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definitions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Preference for Minimally-invasive Surgeries
    • 4.2.2 Technological Advancements in Devices
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Procedure
    • 4.3.2 Risk Associated with the Vein Surgeries
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Treatment Type
    • 5.1.1 Endovenous Ablation
    • 5.1.2 Injection Sclerotherapy
    • 5.1.3 Surgical Ligation/Stripping
  • 5.2 By Product
    • 5.2.1 Ablation Devices
      • 5.2.1.1 Radiofrequency Ablation Devices
      • 5.2.1.2 Laser Ablation Devices
    • 5.2.2 Venous Closure Products
    • 5.2.3 Surgical Products
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Candela Medical (Syneron Medical Ltd)
    • 6.1.2 Medtronic PLC
    • 6.1.3 Boston Scientific (Lumenis Corporation)
    • 6.1.4 El. En SpA Group (Quanta System)
    • 6.1.5 Teleflex Incorporated
    • 6.1.6 Eufoton SRL
    • 6.1.7 Biolitec AG (BioMed Technology Holdings Ltd)
    • 6.1.8 AngioDynamics Inc.
    • 6.1.9 Alma Lasers Ltd
    • 6.1.10 Sciton Inc.
    • 6.1.11 Won Tech Co. Ltd
    • 6.1.12 Dornier MedTech GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS